Prescription profile of medicines for type 2 diabetes mellitus of the municipality of the state of São Paulo
DOI:
https://doi.org/10.15448/1983-652X.2018.2.29288Keywords:
diabetes mellitus, choric disease, drug therapy, drug prescriptions, family health strategy.Abstract
Objective: To analyze the prescriptions of drugs for type 2 diabetes mellitus (T2DM) considering current clinical recommendations, in Family Health Units of Ribeirão Preto, São Paulo.
Materials and Methods: This is a retrospective study carried out through the analysis of medical records of individuals with T2DM who are using medication. The calculated sample size was 150 participants. Socio-demographic, clinical data, prescription of drugs and laboratory test results for glycated hemoglobin were obtained.
Results: The majority of individuals were female (61.3%) and the mean age was 66.4 years. The glycemic control was inadequate in 75.3% of the participants, with an average glycemic hemoglobin of 8.8%. The mean number of drugs prescribed for T2DM treatment was 1.7. In individuals under the age of 60, the prescription of sulfonylureas predominated. Among the elderly, prescription of metformin predominated, followed by sulphonylureas and insulin, respectively. There was an association between inadequate glycemic control and individuals using oral combined therapy [OR=0.32 (95%CI 0.12; 0.80)] and insulin therapy alone or in combination with oral antidiabetic [OR=0.05 (95%CI 0.01; 0.18)]. In addition, there was an association between inadequate glycemic control and individuals with two [OR=0.3 (95%CI 0.13; 0.67)] or three [OR=0.08 (95%CI: 0.01; 0.70)] prescribed medicines.
Conclusion: The glycemic control was inadequate in most participants. Monotherapy was the most frequent treatment, although a considerable proportion of patients used sulfonylurea monotherapy, which is not in accordance with current guidelines for the treatment of T2DM.
References
Sociedade Brasileira de Diabetes. Diretrizes da Sociedade Brasileira de Diabetes 2015-2016. Rio de Janeiro: AC Farmacêutica; 2016.
American Diabetes Association. Standarts of Medical Care in Diabetes – 2017. Diabetes Care. 2017;40(1):S11-S25.
Brasil. Ministério da Saúde. Vigitel Brasil 2016. Brasília: Ministério da Saúde; 2017.
Brasil. Ministério da Saúde. Estratégias para o cuidado da pessoa com doença crônica: diabetes mellitus. Brasília: Ministério da Saúde; 2017.
Pereira SEA, Costa D, Penido R, Batista ANS, Calheiros A, Ferreira GV, Tavares JW, Marins RB, Messias YJ. Fatores de risco e complicações de doenças crônicas não transmissíveis. Ciênc Saúde (Porto Alegre). 2017;10(4):213-9. https://doi.org/10.15448/1983-652X.2017.4.26446
Oliveira MA, Luiza VL, Tavares NUL, Mengue SS, Arrais PSD, Faria MR, Pizzol TSD, Ramos LR, Bertoldi AD. Acesso a medicamentos para doenças crônicas no Brasil: uma abordagem multidimensional. Rev Saúde Pública. 2016;50(Suppl 2):6s. http://dx.doi.org/10.1590/s1518-8787.2016050006161
Prefeitura Municipal de Ribeirão Preto. Secretaria da Saúde. Plano Municipal de Saúde 2014-2017. Ribeirão Preto: Prefeitura Municipal de Ribeirão Preto; 2013.
Silva LMC, Palha PF, Barbosa GR, Protti ST, Ramos AS. Aposentados com diabetes tipo 2 na Saúde da Família em Ribeirão Preto, São Paulo - Brasil. Rev Esc Enferm USP. 2010;44(2):462-8. https://doi.org/10.1590/S0080-62342010000200031
Lima RF, Fontbonne A, Carvalho EMF, Montarroyos UR, Barreto MNSC, Cesse EAP. Factors associated with glycemic control in people with diabetes at the family health strategy in Pernambuco. Rev Esc Enferm USP. 2016; 50(6):937-45. https://doi.org/10.1590/s0080-623420160000700009
Salci MA, Meirelles BHS, Silva DMGV. Primary care for diabetes mellitus patients from the perspective of the care model for chronic conditions. Rev Latino-Am Enfermagem. 2017;25:e2882. https://doi.org/10.1590/1518-8345.1474.2882
Alves da Conceição R, Nogueira da Silva P, Barbosa MLC. Fármacos para o tratamento do diabetes tipo II: uma vista ao passado e um olhar para o futuro. Rev Virtual Quim. 2017;9(2):514-34.
Brummel A, Carlson AM. Comprehensive medication management and medication adherence for chronic conditions. J Manag Care Spec Pharm. 2016;22(1):56-62. https://doi.org/10.18553/jmcp.2016.22.1.56
Costa SS, Rosales RA, Ávila JÁ, Pelzer MT, Lange C. Adesão de idosos com diabetes mellitus à terapêutica: revisão integrativa. Cogitare Enferm. 2017;22(3):e47720. https://doi.org/10.5380/ce.v22i3.47720
May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69-83. https://doi.org/10.1177/2042018816638050
Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164(11):740-51. https://doi.org/10.7326/M15-2650
American Geriatrics Society. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-46. https://doi.org/10.1111/jgs.13702
Cunha GT, Campos GWS. Apoio matricial e atenção primária em saúde. Saúde Soc. 2011;20(4):961-70. https://doi.org/10.1590/S0104-12902011000400013
Grillo MFF. Efeito de diferentes modalidades de educação para o autocuidado a pacientes com diabetes. Rev Assoc Med Bras. 2013;59(4):400-5. https://doi.org/10.1016/j.ramb.2013.02.006
Malta DC, Silva Júnior JB. Plano de ações estratégicas para o enfrentamento das doenças crônicas não transmissíveis no Brasil após 3 anos de implantação, 2011-2013. Epidemiol Serv Saúde. 2014;23(3):389-95. https://doi.org/10.5123/S1679-49742014000300002
Mourão AO, Ferreira WR, Martins MA, Reis AM, Carrillo MR, Guimarães AG, Ev LS. Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial. Int J Clin Pharm. 2013;35(1):79-86 https://doi.org/10.1007/s11096-012-9710-7
Downloads
Published
Issue
Section
License
COPYRIGHT
The submission of originals to Ciência & Saúde implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Ciência & Saúde as the site of original publication.
CREATIVE COMMONS LICENSE
As this journal is open access, the articles are allowed free use in scientific and educational applications, with citation of the source.
According to the type of Creative Commons License (CC-BY 4.0) adopted by Ciência & Saúde , the user must respect the requirements below.
You are free to:
Share — copy and redistribute the material in any medium or format.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
However, only under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests Ciência & Saúde endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
For more details on the Creative Commons license, please follow the link in the footer of this website.